Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of ZYIL1 Following Oral Administration in Healthy Volunteers
PHASE1CompletedINTERVENTIONAL
Enrollment
30
Participants
Timeline
Start Date
December 28, 2020
Primary Completion Date
June 12, 2021
Study Completion Date
June 12, 2021
Conditions
Healthy
Interventions
DRUG
ZYIL1 capsule
NLRP3 inflammasome inhibitor
Trial Locations (1)
382213
Zydus Research Centre, Ahmedabad
All Listed Sponsors
lead
Zydus Lifesciences Limited
INDUSTRY
NCT04731324 - Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of ZYIL1 Following Oral Administration in Healthy Volunteers | Biotech Hunter | Biotech Hunter